Last checked at 23 Apr 2020 07:00
Diaceutics PLC
("Diaceutics" or the "Company")
Â
Posting of Annual Report and Notice of AGM
Â
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it will today post its Annual Report for the year ended 31 December 2019 to shareholders together with the Notice of the 2020 Annual General Meeting ("AGM") and Form of Proxy. Also included with this communication is a deemed consent letter to allow shareholders to register their preference on how they wish to receive shareholder documentation in the future.
Â
The Company will hold its AGM on Tuesday 19 May 2020. Following the UK Government's announcement on 23 March 2020 imposing mandatory social distancing measures, including restrictions on gathering of more than two people, the Company's 2020 AGM will be convened with the minimum quorum of shareholders present in order to conduct the business of the meeting. Shareholders are encouraged to appoint the Chairman of the meeting as their proxy and submit their voting instructions in advance by completing and signing the Form of Proxy accompanying the Notice of the 2020 AGM (or appoint a proxy electronically if their shares are held in CREST) before 2pm on Friday 15 May 2020. Shareholders must not attend the AGM in person.
Â
The Annual Report and Notice of AGM will also be available on the Company's website shortly at www.diaceutics.com.
Â
Enquiries:
Â
Diaceutics PLC | www.diaceutics.com | ||
Peter Keeling, Chief Executive Officer | via Walbrook PR | ||
Philip White, Chief Financial Officer | Â | ||
 |  | ||
Cenkos Securities plc (Nominated adviser and broker) | +44 (0)207 397 8900 | ||
Callum Davidson / Giles Balleny | Â | ||
Michael Johnson (Sales) | Â | ||
 |  | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com | ||
Anna Dunphy | Mob: +44 (0)7876 741 001 | ||
Paul McManus | Mob: +44 (0)7980 541 893 | ||
Â
About Diaceutics
Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com